-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, TkNaivUOMhlTq7D9HPEaq1mZ8sgX1nhjobX4r454xcyTssdKTVvkoCSOEFEoLHhg EtFkW7wFbJG/4tpOwZ57Bg== 0001104659-05-058348.txt : 20051130 0001104659-05-058348.hdr.sgml : 20051130 20051130160404 ACCESSION NUMBER: 0001104659-05-058348 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20051123 ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant FILED AS OF DATE: 20051130 DATE AS OF CHANGE: 20051130 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ABBOTT LABORATORIES CENTRAL INDEX KEY: 0000001800 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 360698440 STATE OF INCORPORATION: IL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-02189 FILM NUMBER: 051234518 BUSINESS ADDRESS: STREET 1: 100 ABBOTT PARK ROAD STREET 2: D-322 AP6D CITY: ABBOTT PARK STATE: IL ZIP: 60064-3500 BUSINESS PHONE: 8479376100 8-K 1 a05-21008_18k.htm CURRENT REPORT OF MATERIAL EVENTS OR CORPORATE CHANGES

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

 

 

FORM  8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

November 23, 2005

Date of Report (Date of earliest event reported)

 

ABBOTT LABORATORIES

(Exact name of registrant as specified in its charter)

 

Illinois

 

1-2189

 

36-0698440

(State or other Jurisdiction

 

(Commission File Number)

 

(IRS Employer

of Incorporation)

 

 

 

Identification No.)

 

100 Abbott Park Road

Abbott Park, Illinois 60064-6400

(Address of principal executive offices)(Zip Code)

 

Registrant’s telephone number, including area code:  (847) 937-6100

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o                                    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o                                    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o                                    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o                                    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


 

Item 2.03

Creation of a Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement of a Registrant

 

Pursuant to the instructions of Item 2.03 of Form 8-K, Abbott Laboratories (“Abbott”) is filing this form to report the creation of the direct financial obligations described below.  The obligations described below are not “off-balance sheet arrangements.”

 

On November 23, 2005, eight of Abbott’s direct or indirect wholly-owned subsidiaries entered 30-month credit agreements with various lenders that, in the aggregate, permit borrowings of up to $1.9 billion (dollar equivalent).  Abbott has guaranteed the obligations of these subsidiaries under these agreements.

 

Borrowings under the credit agreements may be used for general corporate purposes, including repatriation of funds under the American Jobs Creation Act of 2004.  The credit agreements allow prepayment and contain other customary terms and conditions, including representations and warranties, affirmative and negative covenants, events of default, and restrictions on the borrowers, including limitations on mergers and consolidations and a prohibition on substantially changing the nature of any borrower’s business. 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

ABBOTT LABORATORIES

 

 

 

 

Date:    November 30, 2005

By:

  /s/ Thomas C. Freyman

 

 

 

Thomas C. Freyman

 

 

Executive Vice President, Finance
and Chief Financial Officer

 

2

 

 -----END PRIVACY-ENHANCED MESSAGE-----